Spotlight on emerging targets at AACR-NCI-EORTC 2025

Oct. 29, 2025

Leading advances in cancer research, the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlighted some of the field’s most promising innovations. Parabilis Medicines Inc. and Tango Therapeutics Inc. presented their work on potential therapeutic targets that may signal significant shifts in the future of cancer treatment.

BioWorld Science Conferences AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Cancer

Today's news in brief

BioWorld

BioWorld briefs for Aug. 3, 2026.

Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

BioWorld Science

Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...

Seed funding at Adjuvia to treat mitochondrial dysfunction

BioWorld Science

Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...

Replimune’s RP-1 for melanoma wins over FDA adcom

BioWorld

Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...